Back to News
Market Impact: 0.42
Cue Biopharma's CUE-221 Meets Phase 2 Goals In Chronic Hives Study; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Cue Biopharma reported positive topline Phase 2a results for CUE-221 in moderate-to-severe chronic spontaneous urticaria (chronic hives). The therapy met both its primary endpoint and a key secondary endpoint, representing a meaningful clinical-development milestone that could support further advancement of the program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
CUE0.88
More News
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
- China slows humanoid robot IPO rush as hype outruns reality
- Porsche could face another 4,000 job cuts, Handelsblatt reports
- Why is Telix Pharmaceuticals stock sliding today?
- SoftBank plans more than $11 bln bond sale to fund OpenAI bets, Bloomberg reports
- Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search
- Automating Financial Model Updates: A Source-Controlled Workflow